DDInter458 DDInter224
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.[A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving remission. Second-generation BCR-ABL inhibitors like bosutinib inhibit most resistance-conferring BCR-ABL mutations except V299L and T315, thus providing more therapeutic options for patients.[A6901,A17961] Bosutinib was first approved by the FDA in 2012 for the treatment of adult chronic, accelerated, or blast-phase Ph+ CML with resistance or intolerance to prior therapy. On September 26, 2023, bosutinib was also approved by the FDA for the treatment of pediatric CML that is newly diagnosed or resistant/intolerant to prior therapy. This approval was based on favorable results obtained from the open-label, randomized, multicenter trial BFORE that showed a significant improvement in major molecular response, defined as a ≤0.1% BCR ABL ratio on an international scale, with bosutinib treatment.
Cyclosporine {u} (Compound) downregulates {v} (Gene) CDK2
CDK2 {u} (Gene) is bound by {v} (Compound) Bosutinib
Cyclosporine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bosutinib
Cyclosporine {u} (Compound) downregulates {v} (Gene) PSRC1
PSRC1 {u} (Gene) is upregulated by {v} (Compound) Bosutinib
Cyclosporine {u} (Compound) upregulates {v} (Gene) INSIG1
INSIG1 {u} (Gene) is upregulated by {v} (Compound) Bosutinib
Cyclosporine {u} (Compound) is included by {v} (Pharmacologic Class) P-Glycoprotein Inhibitors
P-Glycoprotein Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Bosutinib
Cyclosporine {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Bosutinib
Cyclosporine {u} (Compound) upregulates {v} (Gene) MYC
MYC {u} (Gene) is downregulated by {v} (Compound) Bosutinib
Cyclosporine {u} (Compound) causes {v} (Side Effect) Urinary tract disorder
Urinary tract disorder {u} (Side Effect) is caused by {v} (Compound) Bosutinib
Cyclosporine {u} (Compound) downregulates {v} (Gene) CDK2
CDK2 {u} (Gene) interacts with {v} (Gene) WEE1
WEE1 {u} (Gene) is bound by {v} (Compound) Bosutinib
Cyclosporine {u} (Compound) downregulates {v} (Gene) CSK
CSK {u} (Gene) is regulated by {v} (Gene) PTK2
PTK2 {u} (Gene) is bound by {v} (Compound) Bosutinib
Cyclosporine (Compound) downregulates CDK2 (Gene) and CDK2 (Gene) is bound by Bosutinib (Compound)
Cyclosporine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Cyclosporine (Compound) downregulates PSRC1 (Gene) and PSRC1 (Gene) is upregulated by Bosutinib (Compound)
Cyclosporine (Compound) upregulates INSIG1 (Gene) and INSIG1 (Gene) is upregulated by Bosutinib (Compound)
Cyclosporine (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class) and P-Glycoprotein Inhibitors (Pharmacologic Class) includes Bosutinib (Compound)
Cyclosporine (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Bosutinib (Compound)
Cyclosporine (Compound) upregulates MYC (Gene) and MYC (Gene) is downregulated by Bosutinib (Compound)
Cyclosporine (Compound) causes Urinary tract disorder (Side Effect) and Urinary tract disorder (Side Effect) is caused by Bosutinib (Compound)
Cyclosporine (Compound) downregulates CDK2 (Gene) and CDK2 (Gene) interacts with WEE1 (Gene) and WEE1 (Gene) is bound by Bosutinib (Compound)
Cyclosporine (Compound) downregulates CSK (Gene) and CSK (Gene) is regulated by PTK2 (Gene) and PTK2 (Gene) is bound by Bosutinib (Compound)